Literature DB >> 27626669

KDM4A Coactivates E2F1 to Regulate the PDK-Dependent Metabolic Switch between Mitochondrial Oxidation and Glycolysis.

Ling-Yu Wang1, Chiu-Lien Hung2, Yun-Ru Chen3, Joy C Yang4, Junjian Wang1, Mel Campbell5, Yoshihiro Izumiya6, Hong-Wu Chen1, Wen-Ching Wang7, David K Ann3, Hsing-Jien Kung8.   

Abstract

The histone lysine demethylase KDM4A/JMJD2A has been implicated in prostate carcinogenesis through its role in transcriptional regulation. Here, we describe KDM4A as a E2F1 coactivator and demonstrate a functional role for the E2F1-KDM4A complex in the control of tumor metabolism. KDM4A associates with E2F1 on target gene promoters and enhances E2F1 chromatin binding and transcriptional activity, thereby modulating the transcriptional profile essential for cancer cell proliferation and survival. The pyruvate dehydrogenase kinases (PDKs) PDK1 and PDK3 are direct targets of KDM4A and E2F1 and modulate the switch between glycolytic metabolism and mitochondrial oxidation. Downregulation of KDM4A leads to elevated activity of pyruvate dehydrogenase and mitochondrial oxidation, resulting in excessive accumulation of reactive oxygen species. The altered metabolic phenotypes can be partially rescued by ectopic expression of PDK1 and PDK3, indicating a KDM4A-dependent tumor metabolic regulation via PDK. Our results suggest that KDM4A is a key regulator of tumor metabolism and a potential therapeutic target for prostate cancer.
Copyright © 2016 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27626669      PMCID: PMC5024724          DOI: 10.1016/j.celrep.2016.08.018

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  43 in total

Review 1.  Histone lysine methylation and demethylation pathways in cancer.

Authors:  Radhika A Varier; H T Marc Timmers
Journal:  Biochim Biophys Acta       Date:  2010-10-15

2.  p53 negatively regulates transcription of the pyruvate dehydrogenase kinase Pdk2.

Authors:  Tanupriya Contractor; Chris R Harris
Journal:  Cancer Res       Date:  2011-11-28       Impact factor: 12.701

Review 3.  Regulation of cancer cell metabolism.

Authors:  Rob A Cairns; Isaac S Harris; Tak W Mak
Journal:  Nat Rev Cancer       Date:  2011-02       Impact factor: 60.716

4.  Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases.

Authors:  Johnathan R Whetstine; Amanda Nottke; Fei Lan; Maite Huarte; Sarit Smolikov; Zhongzhou Chen; Eric Spooner; En Li; Gongyi Zhang; Monica Colaiacovo; Yang Shi
Journal:  Cell       Date:  2006-04-06       Impact factor: 41.582

5.  JMJD2A is a novel N-CoR-interacting protein and is involved in repression of the human transcription factor achaete scute-like homologue 2 (ASCL2/Hash2).

Authors:  Dianzheng Zhang; Ho-Guen Yoon; Jiemin Wong
Journal:  Mol Cell Biol       Date:  2005-08       Impact factor: 4.272

Review 6.  How cancer metabolism is tuned for proliferation and vulnerable to disruption.

Authors:  Almut Schulze; Adrian L Harris
Journal:  Nature       Date:  2012-11-15       Impact factor: 49.962

7.  KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes.

Authors:  Lingling Duan; Ganesha Rai; Carlos Roggero; Qing-Jun Zhang; Qun Wei; Shi Hong Ma; Yunyun Zhou; John Santoyo; Elisabeth D Martinez; Guanghua Xiao; Ganesh V Raj; Ajit Jadhav; Anton Simeonov; David J Maloney; Josep Rizo; Jer-Tsong Hsieh; Zhi-Ping Liu
Journal:  Chem Biol       Date:  2015-09-10

8.  Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D.

Authors:  Sook Shin; Ralf Janknecht
Journal:  Biochem Biophys Res Commun       Date:  2007-06-04       Impact factor: 3.575

9.  Specificity and mechanism of JMJD2A, a trimethyllysine-specific histone demethylase.

Authors:  Jean-François Couture; Evys Collazo; Patricia A Ortiz-Tello; Joseph S Brunzelle; Raymond C Trievel
Journal:  Nat Struct Mol Biol       Date:  2007-06-24       Impact factor: 15.369

10.  Structural and evolutionary basis for the dual substrate selectivity of human KDM4 histone demethylase family.

Authors:  Lars Hillringhaus; Wyatt W Yue; Nathan R Rose; Stanley S Ng; Carina Gileadi; Christoph Loenarz; Simon H Bello; James E Bray; Christopher J Schofield; Udo Oppermann
Journal:  J Biol Chem       Date:  2011-09-13       Impact factor: 5.157

View more
  29 in total

1.  The RB-IL-6 axis controls self-renewal and endocrine therapy resistance by fine-tuning mitochondrial activity.

Authors:  S Kitajima; A Yoshida; S Kohno; F Li; S Suzuki; N Nagatani; Y Nishimoto; N Sasaki; H Muranaka; Y Wan; T C Thai; N Okahashi; F Matsuda; H Shimizu; T Nishiuchi; Y Suzuki; K Tominaga; N Gotoh; M Suzuki; M E Ewen; D A Barbie; O Hirose; T Tanaka; C Takahashi
Journal:  Oncogene       Date:  2017-05-08       Impact factor: 9.867

Review 2.  Recent Advances with KDM4 Inhibitors and Potential Applications.

Authors:  Qiong Wu; Brandon Young; Yan Wang; Andrew M Davidoff; Zoran Rankovic; Jun Yang
Journal:  J Med Chem       Date:  2022-07-15       Impact factor: 8.039

3.  2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.

Authors:  Parker L Sulkowski; Christopher D Corso; Nathaniel D Robinson; Susan E Scanlon; Karin R Purshouse; Hanwen Bai; Yanfeng Liu; Ranjini K Sundaram; Denise C Hegan; Nathan R Fons; Gregory A Breuer; Yuanbin Song; Ketu Mishra-Gorur; Henk M De Feyter; Robin A de Graaf; Yulia V Surovtseva; Maureen Kachman; Stephanie Halene; Murat Günel; Peter M Glazer; Ranjit S Bindra
Journal:  Sci Transl Med       Date:  2017-02-01       Impact factor: 19.319

Review 4.  E2F1, a Novel Regulator of Metabolism.

Authors:  Pierre-Damien Denechaud; Lluis Fajas; Albert Giralt
Journal:  Front Endocrinol (Lausanne)       Date:  2017-11-10       Impact factor: 5.555

5.  Health benefits of late-onset metformin treatment every other week in mice.

Authors:  Irene Alfaras; Sarah J Mitchell; Hector Mora; Darisbeth Rosario Lugo; Alessandra Warren; Ignacio Navas-Enamorado; Vickie Hoffmann; Christopher Hine; James R Mitchell; David G Le Couteur; Victoria C Cogger; Michel Bernier; Rafael de Cabo
Journal:  NPJ Aging Mech Dis       Date:  2017-11-20

6.  lncRNA GAS6-AS1 inhibits progression and glucose metabolism reprogramming in LUAD via repressing E2F1-mediated transcription of GLUT1.

Authors:  Jing Luo; Huishan Wang; Li Wang; Gaoming Wang; Yu Yao; Kai Xie; Xiaokun Li; Lin Xu; Yi Shen; Binhui Ren
Journal:  Mol Ther Nucleic Acids       Date:  2021-05-01       Impact factor: 8.886

7.  Triptolide Suppresses Glomerular Mesangial Cell Proliferation in Diabetic Nephropathy Is Associated with Inhibition of PDK1/Akt/mTOR Pathway.

Authors:  Fei Han; Mei Xue; Yunpeng Chang; Xiaoyu Li; Yang Yang; Bei Sun; Liming Chen
Journal:  Int J Biol Sci       Date:  2017-09-21       Impact factor: 6.580

8.  MiR-422a regulates cellular metabolism and malignancy by targeting pyruvate dehydrogenase kinase 2 in gastric cancer.

Authors:  Zhongyuan He; Zheng Li; Xuan Zhang; Kai Yin; Weizhi Wang; Zhipeng Xu; Bowen Li; Lei Zhang; Jianghao Xu; Guangli Sun; Lu Wang; Qing Li; Xiaoxu Huang; Lu Zhang; Diancai Zhang; Hao Xu; Zekuan Xu
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

9.  B-Myb Mediates Proliferation and Migration of Non-Small-Cell Lung Cancer via Suppressing IGFBP3.

Authors:  Xiaoyan Fan; Yitao Wang; Tinghui Jiang; Wei Cai; Yuelei Jin; Yulong Niu; Huifang Zhu; Youquan Bu
Journal:  Int J Mol Sci       Date:  2018-05-16       Impact factor: 5.923

10.  Glyoxalase 1 copy number variation in patients with well differentiated gastro-entero-pancreatic neuroendocrine tumours (GEP-NET).

Authors:  Mingzhan Xue; Alaa Shafie; Talha Qaiser; Nasir M Rajpoot; Gregory Kaltsas; Sean James; Kishore Gopalakrishnan; Adrian Fisk; Georgios K Dimitriadis; Dimitris K Grammatopoulos; Naila Rabbani; Paul J Thornalley; Martin O Weickert
Journal:  Oncotarget       Date:  2017-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.